Introduction {#sec1-1}
============

Urinary tract infection (UTI) is a common ailment diagnosed by clinicians in day-to-day practice in the community as well as in health-care setups. Although the risk factors and patient groups differ in community and hospitals, Gram-negative bacteria, especially *Enterobacteriaceae*, account for a large majority of UTI episodes in both the settings. Cotrimoxazole has long been used for the treatment of uncomplicated UTI in the community. However, over decades of use, it has lost its therapeutic efficacy against Gram-negative uropathogens in most parts of the world. Simple antibiotics such as oral preparations of fluoroquinolones and beta-lactams are currently preferred. However, the rapid development of resistance against quinolones and beta-lactam agents among *Enterobacteriaceae* species recently in most countries has caused great concern for physicians.

High rates of resistance to nalidixic acid, ciprofloxacin, and norfloxacin have been reported in various studies.\[[@ref1][@ref2][@ref3]\] Due to the widespread emergence of extended-spectrum beta-lactamases (ESBLs), AmpC beta-lactamases, and carbapenemases, beta-lactam antibiotics are no longer reliable for empirical therapy in the absence of antibiogram. Although injectable antibiotics such as aminoglycosides, carbapenems, ureidopenicillins, polymyxin B, colistin, and tigecycline may show superior *in vitro* activity against uropathogens resistant to first-line drugs, they are reserved mainly for intractable UTI in hospitalized patients. Fosfomycin is an old antibiotic molecule developed in 1969 in Spain.\[[@ref4]\] Due to the wide antimicrobial spectrum of activity against Gram-positive and Gram-negative uropathogens and convenient oral regimen, it has regained its value for the treatment of UTI. In this current study, we evaluated the *in vitro* antibiotic activity of fosfomycin against uropathogenic *Enterobacteriaceae* isolates in comparison to other antibiotics.

Materials and Methods {#sec1-2}
=====================

A prospective study was performed in our tertiary care hospital in Pondicherry. Urine samples were obtained from both ambulatory and catheterized patients with suspected UTI from various medical and surgical inpatient and outpatient departments in our hospital. Informed consent was obtained from patients before the sample collection. Urine samples were collected aseptically and were sent immediately to the laboratory for further processing.

The samples were processed by standard microbiological procedures. The urine samples were cultured using semi-quantitative method by inoculating plating media (Cystine--lactose--electrolyte-deficient agar) using a calibrated loop. Following inoculation into the plates, wet mount preparations of the samples were observed under a microscope for the presence of pus cells, red blood cells, and microorganisms. After 18--24 h incubation of the cultured plates, colony count was recorded to determine significant bacteriuria. Non-duplicate bacterial isolates with significant colony counts were included in our study and were identified up to species level by biochemical tests. Antibiotic susceptibility was tested by Kirby--Bauer disc-diffusion method against a panel of antibiotics using bacterial suspension matched to 0.5 McFarland\'s standard as inoculum on Muller Hinton agar (MHA). The antibiotics used against *Enterobacteriaceae* isolates were cotrimoxazole (1.25/23.75 μg), nitrofurantoin (300 μg), nalidixic acid (30 μg), norfloxacin (10 μg), cefotaxime (30 μg), gentamicin (10 μg), amikacin (30 μg), fosfomycin (200 μg), and imipenem (10 μg). The zones of inhibition on MHA plates were interpreted according to the Clinical and Laboratory Standards Institute guidelines. For quality control, *Escherichia coli* (ATCC 25922) was used. *Enterobacteriaceae* isolates showing cefotaxime zone ≤27 mm were considered as ESBL producers and were confirmed by combined disc test using ceftazidime (30 μg) and ceftazidime-clavulanic acid discs (30/10 μg).

Results {#sec1-3}
=======

A total of 1500 urine samples were received in the department of microbiology of our hospital, for bacterial culture and antibiotic susceptibility from suspected cases of UTI during the study period. Of 1500 urine samples processed, 582 samples yielded the growth of pathogens. Patients of UTI were mostly from urology, obstetrics, and medicine wards (30.2%, 28%, and 21.6%, respectively). A large fraction of the patients were females (*n* = 353, 61.7%) and 47.6% of the patients belonged to the age group of 21--40 years.

The pathogens were *E. coli* (*n* = 290, 49.8%), *Klebsiella pneumoniae* (*n* = 68, 11.7%), *Citrobacter diversus* (*n* = 8, 1.4%), *Citrobacter freundii* (*n* = 15, 2.6%), *Enterobacter cloacae* (*n* = 3, 0.5%), *Proteus mirabilis* (*n* = 4, 0.7%), *Proteus vulgaris* (*n* = 4, 0.7%), *Pseudomonas aeruginosa* (*n* = 22, 3.8%), *Acinetobacter baumannii* (*n* = 27, 4.6%), non-fermenter Gram-negative bacilli (*n* = 24, 4.1%), Enterococcus spp. (*n* = 63, 10.8%), *Staphylococcus* spp. (*n* = 28, 4.8%), and *Candida* spp. (*n* = 26, 4.5%). *Enterobacteriaceae* accounted for 67.3% (*n* = 392) of the isolates. The microorganism-wise antibiotic resistance pattern is detailed in [Table 1](#T1){ref-type="table"}. EBSL-producing isolates (271, 69.1%) which included 215 *E. coli* and 36 *K. pneumoniae* were identified by ESBL combined disc test. Fosfomycin susceptibility among these ESBL-producing *E. coli* and *K. pneumoniae* was found in 93% and 55.6%, respectively. A total of 269 (68.6%) of our isolates showed resistance to three or more antibiotic classes and were considered as multidrug-resistant (MDR). Fosfomycin resistance among these MDR strains is described in [Table 2](#T2){ref-type="table"}.

###### 

Resistance pattern of *Enterobacteriaceae* isolates

                             Imipenem, *n* (%)   Nitrofurantoin, *n* (%)   Norfloxacin, *n* (%)   Nalidixic acid, *n* (%)   Gentamicin, *n* (%)   Amikacin, *n* (%)   Cefotaxime, *n* (%)   Fosfomycin, *n* (%)   Cotrimoxazole, *n* (%)
  -------------------------- ------------------- ------------------------- ---------------------- ------------------------- --------------------- ------------------- --------------------- --------------------- ------------------------
  *C. diversus* (*n*=8)      1 (12.5)            5 (62.5)                  5 (62.5)               6 (75)                    4 (50)                2 (25)              5 (62.5)              2 (25)                5 (62.5)
  *C. freundii* (*n*=15)     2 (13.3)            11 (73.3)                 10 (66.7)              11 (73.3)                 9 (60)                4 (26.7)            8 (53.3)              1 (6.7)               9 (60)
  *E. coli* (*n*=290)        4 (1.4)             68 (23.4)                 225 (77.6)             265 (91.4)                154 (53.1)            84 (29)             215 (74.1)            19 (6.6)              213 (73.4)
  *E. cloacae* (*n*=3)       0                   1 (33.3)                  0                      0                         1 (33.3)              1 (33.3)            1 (33.3)              0                     1 (33.3)
  *K. pneumoniae* (*n*=68)   7 (10.3)            46 (67.6)                 28 (41.2)              35 (51.5)                 34 (50)               24 (35.3)           36 (52.9)             28 (41.2)             44 (64.7)
  *P. mirabilis* (*n*=4)     1 (25)              4 (100)                   2 (50)                 3 (75)                    1 (25)                4 (100)             2 (50)                1 (25)                4 (100)
  *P. vulgaris* (*n*=4)      1 (25)              4 (100)                   3 (75)                 4 (100)                   2 (50)                2 (50)              4 (100)               1 (25)                4 (100)
  Total (*n*=392)            16 (4.1)            139 (35.5)                273 (69.6)             324 (82.7)                205 (52.3)            121 (30.9)          271 (69.1)            52 (13.3)             280 (71.4)

*C. diversus*=*Citrobacter diversus, C. freundii*=*Citrobacter freundii, E. coli*=*Escherichia coli, E. cloacae*=*Enterobacter cloacae, K. pneumonia*=*Klebsiella pneumonia*, *P. mirabilis*=*Proteus mirabilis, P. vulgaris*=*Proteus vulgaris*

###### 

Fosfomycin resistance among multidrug-resistant isolates

  MDR isolates                 Number of MDR isolates showing fosfomycin resistance, *n* (%)
  ---------------------------- ---------------------------------------------------------------
  *C. diversus* (*n*=5)        1 (20)
  *C. freundii* (*n*=9)        0
  *E. coli* (*n*=206)          11 (5.3)
  *E. cloacae* (*n*=1)         0
  *K*. *pneumoniae* (*n*=41)   15 (36.6)
  *P. mirabilis* (*n*=3)       1 (33.3)
  *P. vulgaris* (*n*=4)        1 (25)
  Total (*n*=269)              29 (10.8)

MDR=Multidrug resistant, *C. diversus*=*Citrobacter diversus, C. freundii=Citrobacter freundii, E. coli*=*Escherichia coli, E. cloacae*=*Enterobacter cloacae, K. pneumonia*=*Klebsiella pneumonia*, *P. mirabilis*=*Proteus mirabilis, P. vulgaris*=*Proteus vulgaris*

Discussion {#sec1-4}
==========

Urinary infections are one of the commonest primary diagnoses in health-care settings. The patients often present with vague complaints and asymptomatic bacteriuria requiring the laboratory confirmation for successful treatment. At present, the emergence of resistance to regularly used antibiotics has left limited therapeutic options for UTI. Hence, there is an increasing need to develop and introduce new antimicrobials for this purpose. However, only a few newer antibiotics are in the pipeline of development. In this scenario, fosfomycin, an older antibiotic, has reclaimed its utility in the treatment of UTI.\[[@ref5]\] Fosfomycin is a phosphonic acid derivative isolated from *Streptomyces* species which acts by inhibiting the first committed step in cell wall synthesis.\[[@ref6]\] It has a broad spectrum of antimicrobial activity against both Gram-positive and Gram-negative bacteria. It is non-toxic, well-tolerated, and is available in oral as well as intravenous formulations. In addition, its commercially available oral formulation (3 g single dose) is most convenient for treating UTI in outpatient departments.\[[@ref7]\]

In the present study, we compared *in vitro* activity of fosfomycin with other antibiotics commonly used for treating UTI to evaluate its utility among the 392 isolates; nalidixic acid (82.7%), cotrimoxazole (71.4%), norfloxacin (69.6%), cefotaxime (69.1%), and gentamicin (52.3%) showed high resistance rates \[[Table 1](#T1){ref-type="table"}\]. Lower rates of resistance were observed for imipenem (4.1%), nitrofurantoin (35.5%), and amikacin (30.9%). Similar high resistance rates to oral antibiotics have been reported in other studies.\[[@ref1][@ref7][@ref8]\] A study from North India by Patwardhan and Singh found lower *in vitro* activity of ampicillin, amoxyclav, cotrimoxazole, nitrofurantoin, and norfloxacin.\[[@ref7]\] In a recent study from South India, Sardar *et al*. found 84.8%, 83.6%, and 79% resistance to amoxicillin-clavulanic acid, cefixime, and norfloxacin in 170 uropathogenic *E. coli* isolates, while imipenem and methenamine mandelate had 100% sensitivity.\[[@ref1]\]

The prevalence of ESBL-producing isolates in UTI varies from 21.8% to 64.8% in various studies.\[[@ref9][@ref10][@ref11]\] In this study, 69.1% (*n* = 271) of our isolates were found to produce ESBL enzymes. This regional variation may be due to the differences in antibiotic usage and infection control measures in hospitals of different areas. The notable finding in our study is the remarkable antibacterial activity of fosfomycin against ESBL-producing uropathogens and strains which were resistant to other commonly used antibiotics. Only 13.3% of our isolates were resistant to it. Fosfomycin sensitivity was noted among 236 (87.1%) of ESBL-producing isolates which included 93% of ESBL-positive *E. coli* strains and to a lesser extent ESBL-positive *K. pneumoniae* (55.6%). Likewise, only 5.3% and 36.6% of MDR *E. coli* and *K. pneumoniae* strains, respectively, were fosfomycin resistant \[[Table 2](#T2){ref-type="table"}\]. Superior sensitivity of fosfomycin observed in our study is in accordance with the findings of several other recent studies.\[[@ref1][@ref7][@ref9][@ref12]\] In a recent study from an apex tertiary care centers of India, Patwardhan and Singh compared susceptibility of uropathogens against oral antibiotics and fosfomycin.\[[@ref7]\] Among 2783 non-repeating *Enterobacteriaceae* urinary isolates, 2730 (98.1%) from patients of all ages and both sexes were fosfomycin sensitive. High *in vitro* susceptibility to fosfomycin was found among 96.5% of ESBL-producing and 91.9% of metallo-β-lactamase-producing isolates. It was also effective against MDR isolates and Gram-positive isolates such as methicillin-resistant *Staphylococcus aureus* (MRSA). There are studies which showed *in vitro* susceptibility of fosfomycin against MDR pathogens such as MRSA, vancomycin-resistant enterococci, ESBL, and AmpC producers.\[[@ref10][@ref12][@ref13][@ref14]\]

The low resistance to fosfomycin observed in our study may be due to the fact that fosfomycin was not in routine clinical use in our hospital unlike other antibiotics. Withdrawal of an antibiotic from routine usage or a prolonged period of therapeutic inoperativeness is more likely to remove the selective pressure on the antibiotic.\[[@ref15]\] Although the risk of selection of fosfomycin-resistant mutants and the development of resistance during therapy has limited its clinical over the past several years, this old antibiotic has been found to regain its antibacterial activity against bacterial pathogens in recent years in several countries including India where it has not been marketed.\[[@ref7]\] Currently, it is recommended for the treatment of uncomplicated UTI in adults and as antibiotic prophylaxis in transurethral diagnostic and surgical procedures.\[[@ref16]\] Fosfomycin has emerged as a major breakthrough in the treatment of UTI due to increasing proportion of colistin-resistant *K. pneumoniae* and *Proteae* with intrinsic nonsusceptibility to colistin in recent years.\[[@ref16]\] Furthermore, it was also found to exert an inhibitory effect on biofilms of MDR uropathogens that essentially plays an important role in the pathogenesis of UTI.\[[@ref14]\]

However, fosfomycin susceptibility also depends on the consumption of the antibiotic. A changing trend with the varied result has been reported overtime where its consumption rate is high. In a study conducted in Spain showed an increase in resistance among *E. coli* urinary isolates where the consumption rate was up to 50%.\[[@ref15]\] Recently, ESBL-producing *Enterobacteriaceae* isolates were reported to carry fosfomycin-resistance determinant resulting in a higher fosfomycin-resistance rate. Wachino *et al*. from Japan identified *FosA3* and *FosC2*, two novel fosfomycin-resistance determinants among CTX-M-producing *E. coli* isolates.\[[@ref17]\] Being located on a plasmid, these resistance genes are transferable and have the potential to disseminate high-level resistance to this antibiotic among other Gram-negative bacterial species.

Conclusions {#sec1-5}
===========

Fosfomycin was the only oral antibiotic which had substantial *in vitro* antimicrobial activity against *Enterobacteriaceae* isolates in our study. ESBL-producing and MDR isolates were mostly sensitive to fosfomycin. Therefore, it could be a promising alternative to currently available first-line antibiotics for the treatment of uncomplicated UTI, especially for a naive population where the consumption rate of fosfomycin is nil.
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